SANP.XC Sanofi SA

Healthcare · Drug Manufacturers - General

6 · Fair Momentum 0.0 · Weak At risk 16y streak

72.71

-9.19%

About the company

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Website

5.67%

104.04%

4.12

87.6B

18.36

3.96

80.01

52-week range

72.7

low 71.8 high 89.2

Dividend deep dive

Sanofi SA, a Drug Manufacturers - General company in the Healthcare sector, currently offers a dividend yield of 5.67%. This is higher than its 5-year historical average of 3.92% and above its 5-year high of 4.38%. According to Yield Theory, the stock appears undervalued, with an implied price of EUR 105.1 compared to its current price of EUR 72.71. The company has maintained a dividend increase streak of 16 years.

Dividend history

Sanofi SA has a 16-year dividend increase streak, classifying it as a CCC Contender. Over the last three years, the dividend has grown at a CAGR of 5.58%. The five-year CAGR stands at 4.47%, indicating consistent growth. Recent annual dividends per share were EUR 3.33 in 2022, EUR 3.56 in 2023, and EUR 3.76 in 2024, with a projected EUR 3.92 for 2025. Dividends are paid annually, typically in May. The dividend has grown steadily from EUR 2.80 in 2014 to EUR 3.76 in 2024.

Dividend safety

Sanofi SA's dividend payout ratio stands at 104.04% based on its earnings per share of EUR 3.96 and a market dividend of EUR 4.12. This indicates the company is paying out more than its current earnings in dividends. The company's leverage is moderate, with a debt-to-equity ratio of 27.372. Liquidity metrics show a current ratio of 1.005 and a quick ratio of 0.201, suggesting limited short-term liquidity. Despite this, the Chowder Number is 10.1, exceeding the 8.0 threshold. Yield Theory suggests the stock is undervalued, with the current 5.67% yield well above its 5-year average of 3.92%.

Key risks

The dividend payout ratio of 104.04% suggests the company is paying out more than it earns.
A quick ratio of 0.201 indicates low short-term liquidity.
The current ratio of 1.005 also points to constrained short-term asset coverage.
While debt-to-equity is 27.372, persistent high payout could strain finances.